The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Treating transplant-ineligible patients with myeloma in Italy
In this video, Alessandro Gozzetti, MD, PhD, AOU Senese, Siena, Italy, outlines the two treatment strategies commonly used in Italy for treating transplant-ineligible patients with multiple myeloma (MM). Dr Gozzetti highlights that although daratumumab plus lenalidomide and dexamethasone is the treatment regimen of choice in most patients, a bortezomib-containing combination therapy is preferred for patients with renal insufficiency. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
